Lingual lesions with orally disintegrating risperidone.
Dowling
Nanette M
NM
Megna
James L
JL
Burgdorf
Andrew
A
Yashaswi
Veena
V
D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D008297:Male; D009061:Mouth Mucosa / Q000378:metabolism; D011618:Psychotic Disorders / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D014060:Tongue Diseases / Q000139:chemically induced*
D014150:Antipsychotic Agents; D018967:Risperidone